logo
‘Gas station heroin' is technically illegal and widely available. Here are the facts

‘Gas station heroin' is technically illegal and widely available. Here are the facts

WASHINGTON — Health officials want you to think twice before buying one of those brightly colored little bottles often sold at gas stations, convenience stores and smoke shops.
Sometimes called 'gas station heroin,' the products are usually marketed as energy shots or cognitive supplements but actually contain tianeptine, an unapproved drug that can be addictive and carries risks of serious side effects.
U.S. poison control centers have reported a steady rise in calls linked to the drug for more than a decade. And last month the Food and Drug Administration sent a warning to health professionals about 'the magnitude of the underlying danger or these products.'
Here's what to know about gas station heroin.
Tianeptine is approved in a number of foreign countries as an antidepressant, usually as a low-dose pill taken three times a day. But it has never been approved by the FDA for any medical condition in the U.S.
Additionally, the drug cannot legally be added to foods and beverages or sold as a dietary supplement — something the FDA has repeatedly warned U.S. companies about.
Still, under-the-radar firms sell tianeptine in various formulas, often with brand names like Zaza, Tianaa, Pegasus and TD Red. Although that is technically illegal, the FDA does not preapprove ingredients added to supplements and beverages.
'It's kind of this gray area of consumer products, or supplements, where the contents are not regulated or tested the way they would be with a medication,' said Dr. Diane Calello of the New Jersey Poison Information and Education System.
Last year, Calello and her colleagues published a study documenting a cluster of emergency calls in New Jersey tied to a flavored elixir called Neptune's Fix. People experienced distress, rapid heartbeat, low blood pressure and seizures after drinking it. More than a dozen of the 20 patients had to be admitted for intensive care.
Many tianeptine products claim — without evidence or FDA approval — to help users treat medical conditions, including addiction, pain and depression.
In 2018, the FDA issued a warning letter to the maker of a product called Tianna, which claimed to provide 'an unparalleled solution to cravings for opiates.'
While tianeptine is not an opioid, the drug binds to some of the same receptors in the brain, which can temporarily produce effects akin to oxycodone and other opioids. Tianeptine also carries some of the same physiological risks of opioids, including the potential to dangerously depress breathing.
'That's what tends to get people into trouble,' said Dr. Hannah Hays of Nationwide Children's Hospital in Columbus, Ohio. 'They use it for opioid-like effects or to self-treat opioid withdrawal and that can lead to slow breathing and problems like that.'
People dealing with opioid addiction, pain, depression, anxiety and other conditions should see a health professional to get a prescription for FDA-approved treatments, Hays said.
Experts aren't sure but national figures show a big rise in emergency calls involving the drug.
Calls to poison control centers increased 525% between 2018 and 2023, according to a data analysis published earlier this year. In about 40% of cases, the person had to seek medical care, with more than half of them needing critical care.
One explanation for the rise in calls is simply that more Americans are using the products.
But experts also say that the products are triggering more emergencies as they become more potent and dangerous. And the researchers in New Jersey who analyzed Neptune's Fix found that the liquid also contained synthetic cannabis and other drugs.
'You never quite know what's in that bottle,' Calello said. 'It's important for people to know that even if they have used a product before, they could get a bottle that contains something very different from what they're looking for.'
Tianeptine is not included in the federal Controlled Substances Act, which bans or restricts drugs that have no medical use or have a high potential for abuse, such as heroin, LSD and PCP. But about a dozen states have passed laws prohibiting or restricting tianeptine, including Alabama, Georgia, Michigan, Minnesota, Ohio and Tennessee.
In some cases, those laws have led to more cases of withdrawal among users of tianeptine, which can be chemically addictive. But state data also show some success in reducing harm tied to the drug.
Until recently, Alabama had the highest rate of tianeptine-related calls in the southern U.S., which increased more than 1,400% from 2018-21. But after the state restricted tianeptine in 2021, calls began modestly decreasing while calls across other Southern states continued to climb.
Perrone writes for the Associated Press.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR
FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR

Yahoo

time12 hours ago

  • Yahoo

FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR

Merck & Co., Inc. (NYSE:MRK) is one of the . On July 2, Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted and granted priority review to its supplemental Biologics License Application for WINREVAIR. Merck & Co., Inc.'s (NYSE:MRK) WINREVAIR was previously approved in 2024 for treating adults with pulmonary arterial hypertension. The treatment aims to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The current application seeks to update the US product label based on the results of the Phase 3 ZENITH trial. A close-up of a person's hand holding a bottle of pharmaceuticals. The ZENITH trial is notable for being the first Phase 3 PAH study to use a primary endpoint focused solely on major morbidity and mortality events. The results demonstrated a 76% reduction in the risk of a composite outcome of all-cause death, lung transplantation, and hospitalization for PAH lasting 24 hours or more, compared to placebo. The FDA has set a target action date of October 25, 2025, under the Prescription Drug User Fee Act. Merck & Co., Inc. (NYSE:MRK) is a leading healthcare company that operates through two main segments including the Pharmaceutical and Animal Health Segments. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

2 Stocks to Buy on the Dip and Hold for 10 Years
2 Stocks to Buy on the Dip and Hold for 10 Years

Yahoo

time19 hours ago

  • Yahoo

2 Stocks to Buy on the Dip and Hold for 10 Years

Novo Nordisk's shares look attractive after a terrible performance over the past 12 months. DexCom has significant room to grow in its core market, despite disappointing results last year. 10 stocks we like better than Novo Nordisk › One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities. Two great examples today in the healthcare sector are Novo Nordisk (NYSE: NVO) and DexCom (NASDAQ: DXCM). Although these two corporations have encountered significant headwinds since last year, they could deliver market-beating returns to investors who initiate positions today and stick with them for at least a decade. Novo Nordisk is coming off clinical setbacks and unimpressive financial results, at least by its lofty standards. The stock has significantly underperformed the market over the trailing-12-month period. But after this beating, the company's shares look attractive. Here are several reasons why. First, although Novo Nordisk's eternal rival, Eli Lilly, appears to be taking the lead in the fast-growing weight management market, the former still has excellent prospects in this rapidly expanding therapeutic area. Novo Nordisk's Wegovy continues to grow its sales at a good clip, and the company is awaiting approval from the U.S. Food and Drug Administration for an oral formulation of this popular medicine. Further, Novo Nordisk has promising internally developed pipeline candidates, such as amycretin, which recently entered phase 3 studies. The Denmark-based drugmaker has also enhanced its pipeline in this area, thanks to licensing deals and acquisitions. Second, Novo Nordisk has been working on diversifying its lineup and currently has promising pipeline candidates outside of its core treatment areas of diabetes and obesity. Novo Nordisk is developing medicines for conditions including hemophilia, Parkinson's disease, sickle cell disease, Alzheimer's disease, and others. Third, after being southbound for the past 12 months, Novo Nordisk's shares look reasonably valued. The company's forward price-to-earnings ratio is 16.8, compared to the 16.3 average for the healthcare industry. Novo Nordisk's financial results over the past year have been terrific by industry standards, but not quite what the market expected. That may have justified the sell-off, but at current levels, the stock looks attractive. Finally, Novo Nordisk is a solid dividend-paying company. It has increased its annual dividend per share by almost 284% over the past decade, while offering a forward yield of 2.3%. That's not exceptional, but it's above the S&P 500 index's average of 1.3%. Novo Nordisk is well-positioned to bounce back and deliver strong returns in the next decade as it rides weight management (and other) tailwinds. DexCom is a leading diabetes-focused medical device company. It develops continuous glucose monitoring (CGM) systems that help diabetics with constant blood sugar level measurements. DexCom has been successful thanks to the increased adoption of this innovative technology. Unlike blood glucose meters that are manually operated, use pesky and painful fingersticks, and can only tell a person's sugar level at one point in time, CGM devices are constantly monitoring things and automatically make measurements as often as every five minutes. Rrevenue and earnings have grown rapidly over the past decade, but the company hit a speed bump last year when its top-line growth slowed considerably, partly due to higher-than-expected rebates in the U.S., resulting in lower revenue per patient. That said, these are short-term issues that do little to impact the company's long-term prospects. And on that front, there are still plenty of reasons to be excited about DexCom's future. Consider that the company has ample room to grow, even in the U.S., a country that enjoys higher CGM penetration than most others. However, as DexCom has consistently pointed out, the population of patients who use CGM continues to lag behind those who are eligible for third-party coverage -- in other words, many people could obtain the technology paid for by insurers but have not yet opted in. Further, there is a vast worldwide opportunity, since only a tiny percentage of the diabetics in the world use CGM technology. Though many are in countries where DexCom does not do business, the company has generally increased its addressable market by entering new geographies. In the next 10 years, expect the company to do the same while benefiting from greater insurance coverage for CGM -- third-party payers, including governments, have been more willing to foot the bill because of the technology's benefits. All that should lead to consistent revenue and earnings growth for the medical device specialist. The stock has crushed the market in the past decade using this formula. In my view, it is well-positioned to do the same through 2035. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. 2 Stocks to Buy on the Dip and Hold for 10 Years was originally published by The Motley Fool

Brighten Your Skin Safely: Why Hydroquinone 4% Cream Remains the Gold Standard for Hyperpigmentation
Brighten Your Skin Safely: Why Hydroquinone 4% Cream Remains the Gold Standard for Hyperpigmentation

Time Business News

time21 hours ago

  • Time Business News

Brighten Your Skin Safely: Why Hydroquinone 4% Cream Remains the Gold Standard for Hyperpigmentation

In the world of skincare, achieving a flawless, even-toned complexion is often a top goal. Whether you're dealing with dark spots, melasma, age spots, or acne scars, hydroquinone cream 4 percent remains one of the most trusted and dermatologist-recommended treatments for fading hyperpigmentation. If you're looking to understand how it works, what results to expect, and where to buy hydroquinone 4% cream online, this in-depth guide is for you. What is Hydroquinone 4% Cream? Hydroquinone is a skin-lightening agent that works by inhibiting tyrosinase, an enzyme responsible for the production of melanin (the pigment that gives skin its color). At a concentration of 4%, it's considered the most effective over-the-counter strength for treating moderate to severe hyperpigmentation. Common skin concerns treated with hydroquinone 4% cream include: Melasma Age spots Post-inflammatory hyperpigmentation (PIH) Acne scarring Freckles and sunspots This strength is typically recommended for individuals who have previously used lighter concentrations (like 2%) and are looking for more dramatic, faster results. Benefits of Hydroquinone 4% Cream The advantages of using hydroquinone cream at 4% strength are clear and well-documented: Rapid Fading of Dark Spots: Noticeable improvement in 4–6 weeks of consistent use. Noticeable improvement in 4–6 weeks of consistent use. Evens Out Skin Tone: Helps reduce blotchiness and patchiness. Helps reduce blotchiness and patchiness. Minimal Downtime: Non-invasive and easy to apply at home. Non-invasive and easy to apply at home. Dermatologist Recommended: A top choice in skin clinics for decades. People often search for terms like 'hydroquinone 4 cream results' or 'hydroquinone 4 cream before and after pictures' to see real-life transformations. A consistent regimen, combined with sun protection, makes all the difference. How to Use Hydroquinone 4% Cream Correctly To ensure maximum benefits while avoiding irritation or side effects, follow these steps: Cleanse: Wash your face with a mild, non-irritating cleanser. Apply Thin Layer: Use a small amount of hydroquinone cream on the affected area only. Moisturize: Wait a few minutes and apply a hydrating, non-comedogenic moisturizer. Sunscreen is Non-Negotiable: Always use broad-spectrum SPF 30 or higher during the day. Use Once Daily: Usually applied at night, unless otherwise instructed by a healthcare provider. Avoid using with products that contain benzoyl peroxide, AHAs, or vitamin C initially, as they may cause irritation. Hydroquinone Cream 4% vs. Other Bleaching Creams Some people wonder whether 'hydroquinone bleaching cream' is safe or if they should opt for natural alternatives. While hydroquinone is technically a bleaching agent, it is FDA-approved and widely used in clinical dermatology. Compared to natural alternatives, hydroquinone: Works faster and more effectively Is supported by decades of clinical studies Targets pigment directly at the source (melanin production) It's important to follow usage instructions and take breaks (often 3 months on, 1 month off) to prevent overuse. Understanding Hydroquinone 4 Cream Price and Accessibility The hydroquinone 4 cream price can vary significantly depending on the brand and where you purchase it. In the U.S., prescription formulations may cost $60–$100 or more. Fortunately, you can buy hydroquinone online from trusted international pharmacies like OKDERMO at a much more affordable rate—without a prescription in many regions. This makes it easier to access professional-grade skincare without paying a premium or visiting a dermatologist. Where to Buy Hydroquinone 4 Cream Online Safely While some turn to large marketplaces and search 'hydroquinone 4 cream Amazon,' it's important to be cautious. Not all listings guarantee authenticity or proper storage. Buying from a specialty skincare provider like OKDERMO ensures: Pharmaceutical-grade product Proper packaging and shipping Trusted customer service and global delivery OKDERMO carries Melalite 4 Cream, a well-known brand that delivers powerful skin-lightening results using 4% hydroquinone. Before and After Expectations Seeing hydroquinone 4 cream before and after pictures can be highly motivating. Most users report visible changes within 4 to 6 weeks, with optimal results seen after 2 to 3 months of regular use. Note: Hydroquinone results are not immediate. It requires consistent application, sun protection, and patience. Once the desired skin tone is achieved, dermatologists typically recommend discontinuing use or switching to maintenance products to avoid over-depigmentation. Safety and Precautions While hydroquinone is safe for most users, it's important to use it correctly and monitor your skin's reaction: Do not use on broken or inflamed skin. Avoid long-term use without breaks. A 3-month cycle is often recommended. A 3-month cycle is often recommended. Consult a dermatologist if you experience severe redness, burning, or unusual pigmentation changes. Always do a patch test before applying it to larger areas. Final Thoughts If you're seeking a reliable and effective solution to dark spots and uneven skin tone, hydroquinone 4% cream stands out as the gold standard. Backed by decades of medical use and clinical evidence, it delivers visible results in a matter of weeks. Rather than risking unknown sellers or overpriced prescriptions, buy directly from a trusted source. OKDERMO's Melalite 4 Cream offers pharmaceutical-grade strength and proven outcomes at an affordable price—no prescription required. TIME BUSINESS NEWS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store